This is a working overview of dihexa, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | For lyophilized powder; avoid repeated freeze-thaw. |
| Appearance | White to off-white powder | Common for lyophilized peptides. |
| Solubility | Soluble in water and aqueous buffers | Limited solubility in nonpolar solvents. |
| Typical analytical method | Reverse-phase HPLC and mass spectrometry | Used for purity and identity checks. |
| Typical purity specification | 95% or greater by HPLC area | Supplier values vary; not a biological potency measure. |
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
When Cooper boarded Faith 7 at 6:36 AM on the morning of May 14, he found a little gift that had been left for him. Alan Shepard, knowing that Cooper would have a new version of the urine containment device that Shepard did not have on his Mercury-Redstone 3 flight (forcing him to relieve himself during a long countdown hold), had left behind a suction-cup pump as a joke. Instructions on the handle said, "Remove Before Launch". The gift did not make the trip. Neither did Cooper that day. Various problems with radar in Bermuda and the diesel engine that rolled back the gantry caused the launch to be cancelled until May 15.
== Background == Beginning life as Claus Cecil Borberg, Bülow was the son of Danish author and playwright Svend Borberg (1888–1947) and his wife, Jonna von Bülow-Plüskow (1900–1959). His father was accused, though later cleared, of being a Nazi collaborator for his activities during the Second World War in the German occupation of Denmark. After graduating from university with a degree in law and becoming an apprentice in the legal profession, Claus chose to be known by his maternal surname, Bülow, instead of his father's surname, Borberg. His mother was the daughter of Frits Bülow von Plüskow, Danish Minister of Justice from 1910 to 1913, president of the upper chamber of the Danish Parliament from 1920 to 1922 and a member of the old Dano-German noble Bülow family, originally from Mecklenburg. Von Bülow graduated from Trinity College, Cambridge, and practised law in London in the 1950s before working as a personal assistant to J. Paul Getty. While he had a variety of duties for Getty, Bülow became very familiar with the economics of the oil industry. Getty wrote that Bülow showed "remarkable forbearance and good nature" as his occasional whipping boy, and Bülow remained with Getty until 1968. On 6 June 1966, von Bülow married Sunny, the American ex-wife of Prince Alfred von Auersperg. He worked on and off as a consultant to oil companies. Sunny already had a son and a daughter from her first marriage; together, she and Bülow had a daughter, Cosima von Bülow, born on 15 April 1967 in New York City.
Dustin Andrew Fletcher (born 7 May 1975) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). He is widely acknowledged as one of the finest defenders in the history of the league, and one of only six players in the history of the VFL/AFL competition to play 400 games. Fletcher is a member of the Australian Football Hall of Fame, and a Legend in the Essendon Hall of Fame.
For centuries, hair removal has long shaped gender roles, served to signify social status and defined notions of femininity and the ideal "body image". In early periods, the condition of being hairless was mostly done as a way to keep the body clean, using flint, seashells, beeswax and various other depilatory utensils and exfoliator substances, some highly questionable and highly caustic. Ancient Rome also associated hair removal with status: a person with smooth skin was associated with purity and superiority. Removing body hair was done by both men and women. Psilothrum or psilotrum (Ancient Greek: ψίλωθρον) and dropax (Ancient Greek: δρῶπαξ) were depilatories in ancient Greece and Rome. An alipilus (Ancient Greek: παρατίλτριος) was a slave who attended bathers, removing unwanted body hair. The same practice applied to women, who were served by female slaves called παρατίλτριαι (the plural of παρατίλτρια, the feminine form of παρατίλτριος). In Ancient Egypt, besides being a fashion statement for affluent Egyptians of all genders, hair removal served as a treatment for louse infestation, which was a prevalent issue in the region. Very often, they would replace the removed head hair with a Nubian wig, which was seen as easier to maintain and also fashionable. Ancient Egyptian priests also shaved or depilated all over daily, so as to present a "pure" body before the images of the gods.
Sources: en.wikipedia.org
In March 2025, he was appointed one of the co-chairs of the Global Task Force for the International Decade of Indigenous Languages (2022–2032), representing Indigenous peoples' organizations from Africa.
says that none will be opened after the Cleves, Ohio, location, failed their expectations and closed in September 2024 after opening in February of the previous year. In 2025, Roy Rogers will open a third location in Leesburg, Virginia, where it has already has a strong presence as well as one in Cherry Hill, New Jersey.
=== Approved drugs === Aripiprazole (Abilify) – dopamine D2 and D3 partial agonist, serotonin 5-HT1A and 5-HT7 receptor partial agonist, serotonin 5-HT2A and 5-HT2B receptor antagonist or inverse agonist, and atypical antipsychotic Risperidone (Risperdal) – dopamine D2 and D3 receptor antagonist, serotonin 5-HT1B, 5-HT2A, 5-HT2C, and 5-HT7 receptor antagonist or inverse agonist, α1- and α2-adrenergic receptor antagonist, histamine H1 receptor inverse agonist, and atypical antipsychotic
Sources: en.wikipedia.org
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.
Reverse-phase HPLC can estimate purity, while mass spectrometry helps confirm molecular mass. These methods do not prove biological effects. Lot-specific certificates may provide additional data.
It is not an approved medicine in major jurisdictions. Depending on the country and marketing claims, it may be treated as a research chemical or unapproved substance. Import and sale rules vary.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.